51例耐药肺结核的疗效观察  

Clinical observation of therapeutic effect of 51 patients with multi-drug resistant pulmonary tuberculosis

作　　者：曹兆兰[1] 李铁成[1] 

机构地区：[1]连云港市第四人民医院,江苏连云港222000

出　　处：《临床肺科杂志》2015年第9期1599-1602,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的分析2011年纳入中盖项目的耐药肺结核患者治疗转归情况。方法对痰涂片结核分枝杆菌阳性的标本进行基因芯片耐多药检测,同时进行罗氏培养、比例法药敏试验和菌种鉴定。采用标准化治疗方案6ZAm(Cm)LFx(Mfx)PAS(EMB)Pto/18ZLFx(Mfx)PAS(EMB)Pto进行治疗24个月(注射期6个月,非注射期18个月),治疗过程中对患者进行痰涂片、痰菌培养、肝肾功能、血尿常规、胸片等项目的检查和检测。治疗全程实施DOTS管理。结果耐药肺结核治疗成功率54.9%(28/51),其中MDR-TB治疗成功率56.76%(21/37),耐RFP非MDR-TB治疗成功率70%(7/10),XDR-TB治疗成功率0%。结论中盖项目中采取标准化治疗方案治疗耐药肺结核取得较满意的近期治疗效果。Objective To analyze the therapeutic effect of patients with drug-resistant tuberculosis received treatment at the year of 2011. Methods All smear-positive sputum was tested by gene chip and L-J culture method, and the strain identification was performed. The patients were treated with standardized treatment regimen （6ZAm （Cm） LFx（Mfx） PAS（EMB） Pto/18ZLFx（Mfx） PAS（EMB） Pto）. They were treated for 24 months, including 6 months for injection and 18 months without injection. During the period of treatment, sputum smear and culture were performed, hepatic and renal function, blood and urine regular test were measured, and chest radiographs were also performed regularly. DOTS was adopted throughout the therapeutic course. Results The total success rate was 54. 9% （7/10）, including 56.76% for MDR-TB （21/37）, 70% for single rifampin-resistant TB （7/10）, and 0% for XDR-TB respectively. Conclusion The short term effect of standardized treatment regimen for patients with drug-resistant tuberculosis is satisfactory at the end of treatment.

关 键 词：肺结核 耐药 疗效 

分 类 号：R521[医药卫生—内科学]